Clinical trial
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has…
NCT00005048 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00005048 |
|---|---|
| Title | Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Safety and Efficacy of One Hour Weekly Taxol Infusion and Estramustine in Hormone Refractory Prostate Cancer |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | estramustine phosphate sodium, paclitaxel |
| Start date | Apr 1, 1997 |
| Primary completion | Aug 1, 2000 |
| First posted | Jun 18, 2004 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: